Katsuhito Nagai
Overview
Explore the profile of Katsuhito Nagai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagai K, Tamura M, Murayama R, Fukuno S, Ito T, Konishi H
PLoS One
. 2023 Sep;
18(9):e0291822.
PMID: 37733713
Background: Menthol exerts relaxing, antibacterial, and anti-inflammatory activities, and is marketed as a functional food and therapeutic drug. Aim: In the present study, the effects of menthol on the expression...
2.
Fukuno S, Nagai K, Kurotobi A, Sahori Y, Nakagawa R, Nomura R, et al.
Xenobiotica
. 2023 Aug;
53(5):421-428.
PMID: 37640546
Danazol (DNZ) is a synthetic androgen derivative used for the treatment of intractable hematological disorders. In this study, we investigated the effects of DNZ on CYP3A activity in hepatic and...
3.
Nagai K, Fukuno S, Miura T, Yasuda-Imanishi E, Konishi H
Drug Res (Stuttg)
. 2023 Aug;
73(8):473-475.
PMID: 37591260
Bardoxolone methyl (BX) is expected to be an innovate therapeutic agent for chronic kidney disease (CKD). The aim of the present study was to examine whether the expression of subtypes...
4.
Aoe M, Esaki S, Ikejiri M, Ito T, Nagai K, Hatsuda Y, et al.
Pharmacy (Basel)
. 2023 Jan;
11(1).
PMID: 36649026
During the coronavirus disease 2019 (COVID-19) pandemic, online-based learning has become mainstream in many countries, and its learning outcomes have been evaluated. However, various studies have shown that online-based learning...
5.
Fukuno S, Nagai K, Yamaoka S, Yamada F, Mizumoto H, Ito T, et al.
J Pharm Pharmacol
. 2021 Dec;
74(2):200-207.
PMID: 34923583
Objectives: We investigated the pharmacokinetic interaction of doxorubicin (DOX) with phenytoin (PHT) and the underlying mechanism in rats to clarify why the serum PHT concentration decreases despite the impaired PHT...
6.
Nagai K, Fukuno S, Shiota M, Tamura M, Yabumoto S, Konishi H
Anticancer Res
. 2021 Dec;
41(12):6105-6112.
PMID: 34848465
Background/aim: Epirubicin (EPI), an epimer of doxorubicin (DOX), and DOX are anthracycline agents with broad-spectrum antitumor activity. The aim of the present study was to elucidate the transport characteristics of...
7.
Nagai K, Ryuno Y, Iwanami Y, Omotani S, Fukuno S, Hatsuda Y, et al.
PLoS One
. 2021 Nov;
16(11):e0259400.
PMID: 34752482
Background: The use of enteral nutrients plays a highly important role in accurate nutrition management, but limited information is currently available on the cautionary points of semi-solid enteral nutrients. Aim:...
8.
Nagai K, Omotani S, Shibano M, Kobayashi A, Ito A, Nishimura I, et al.
Int J Med Sci
. 2019 Oct;
16(9):1283-1286.
PMID: 31588194
The use of semi-solid enteral nutrients plays an extremely important role in accurate nutrition management. In the present study, we compared the pharmacokinetic profile of orally administered carbamazepine (CBZ) in...
9.
Fukuno S, Nagai K, Yamamoto K, Tanimura T, Nabe T, Konishi H
Biopharm Drug Dispos
. 2019 Jun;
40(7):225-233.
PMID: 31215040
The study examined the effect of doxorubicin (DOX) on the hepatic expression of CYP2C and its activity for metabolizing tolbutamide (TB), a specific CYP2C substrate, in rats and whether the...
10.
Nagai K, Fukuno S, Omachi A, Omotani S, Hatsuda Y, Myotoku M, et al.
Drug Metab Pers Ther
. 2019 Mar;
34(1).
PMID: 30840584
Background Menthol is widely used as a constituent of functional foods and chemical drugs. In the present study, we investigated changes in the expression of cytochrome P450 isoform CYP3A4mRNA after...